Furosemide Use to Fill the Bladder of Pediatric Females Awaiting Pelvic Ultrasound

Sponsor
Connecticut Children's Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05098366
Collaborator
(none)
100
1
2
10.1
9.9

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate whether or not furosemide causes the bladder to fill faster than IV fluids alone so that a pelvic ultrasound exam can be performed.

Condition or Disease Intervention/Treatment Phase
Early Phase 1

Detailed Description

Trans-abdominal pelvic ultrasound is the standard imaging modality for diagnosis of ovarian torsion in the pediatric population, however this requires that the patient have a full bladder at the time of imaging. This study will investigate whether low dose furosemide in addition to IV fluid boluses may provide a fast, effective, and non-invasive means to fill the bladder of pediatric females awaiting pelvic US. The target population are females age 8 to 18 years seen in the emergency room at Connecticut Children's Medical Center who are undergoing a trans-abdominal pelvic ultrasound to assess for ovarian torsion. Enrolled patients will be randomized to the control (IVF bolus only) group vs. the intervention (IVF bolus + furosemide) group and will undergo point-of-care US (POCUS) and bladder scanner evaluation of the bladder every 30 minutes until the bladder is determined to be full.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled trialRandomized controlled trial
Masking:
Single (Participant)
Primary Purpose:
Diagnostic
Official Title:
Utilization of Furosemide to Expedite Bladder Filling in Pediatric Females With Suspected Ovarian Torsion Awaiting Pelvic Ultrasound
Actual Study Start Date :
May 29, 2021
Anticipated Primary Completion Date :
Apr 1, 2022
Anticipated Study Completion Date :
Apr 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Furosemide

Participants will receive a 20mL/kg (max 1000mL) IV fluid bolus and a 0.1mg/kg (max 5mg) furosemide dose

Drug: Furosemide
0.1mg/kg (max 5mg) of IV furosemide
Other Names:
  • Lasix
  • Placebo Comparator: IV fluids

    Participants will receive a 20mL/kg (max 1000mL) IV fluid bolus and an IV fluid flush

    Drug: Normal saline
    20mL/kg (max 1000mL) normal saline bolus plus a normal saline flush
    Other Names:
  • Intravenous fluids
  • IV fluids
  • Outcome Measures

    Primary Outcome Measures

    1. The time from initiation of the intervention to the time that the bladder reaches large, ovoid shape on POCUS exam [Through study completion, about 3 hours]

      Initiation of the intervention is defined as administration of furosemide vs. normal saline flush.

    Secondary Outcome Measures

    1. The correlation between bladder volume as calculated on POCUS exam of a large, ovoid bladder and bladder volume as reported by bladder scanner [Through study completion, about 3 hours]

      Measurements will be completed every 30 minutes through study completion

    2. Number and nature of all reports of adverse events related to furosemide administration [From time of intervention until final disposition, about 6 hours]

      Adverse events include signs of severe dehydration, allergic reaction, and electrolyte abnormality

    3. The time from initiation of the intervention to the time of completion of successful radiology-performed pelvic US [About 3 hours]

    4. The time from initiation of intervention to the time of admission or discharge order placement [From time of intervention until final disposition, about 6 hours]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    8 Years to 18 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Females age 8-18yrs seen in the ED at CCMC who are undergoing a trans-abdominal pelvic ultrasound to assess for ovarian torsion

    2. Ability of patient (if 18yrs) or parent/legal guardian to sign a written informed consent

    Exclusion Criteria:
    1. History of renal, genitourinary, or pelvic anomalies
    1. Eg: Chronic kidney disease, anuria, vesicoureteral reflux, ureteral obstruction, urologic reconstructive surgery, suprapubic or pelvic surgery, indwelling urethral catheter, oophorectomy, bicornate uterus
    1. Patients with multiple chronic illnesses or systemic neurologic abnormality
    1. Eg: Bronchopulmonary dysplasia, tracheostomy, gastrostomy tube dependence, cerebral palsy, severe developmental delay, mitochondrial disorder, congenital heart disease, cardiomyopathy, chronic kidney disease, diabetes
    1. Patients with known pregnancy

    2. Patients deemed to be critically ill

    1. Mental status changes, signs of end organ damage, hypotension
    1. Contraindication to giving Furosemide
    1. Allergy to sulfonamide medications, severe dehydration, hypotension, underlying electrolyte abnormality, underlying renal disease
    1. History of previous diuretic use within the past year

    2. Patients who self-report their bladder as being full at the time of enrollment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Connecticut Children's Medical Center Hartford Connecticut United States 06106

    Sponsors and Collaborators

    • Connecticut Children's Medical Center

    Investigators

    • Principal Investigator: Candice Jersey, D.O., Connecticut Children's Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Candice Jersey, Pediatric Emergency Medicine Fellow, Connecticut Children's Medical Center
    ClinicalTrials.gov Identifier:
    NCT05098366
    Other Study ID Numbers:
    • 21-008
    First Posted:
    Oct 28, 2021
    Last Update Posted:
    Oct 28, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Candice Jersey, Pediatric Emergency Medicine Fellow, Connecticut Children's Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 28, 2021